Partial
Mostly Aligned
Patient Risk:
Medium
Summary
Most mechanism/symptom-relief statements are consistent with the label, but several indication-phrasing and prescriber-frequency/general-use claims are not supported by the provided FDA label text, and high-priority safety label elements (e.g., boxed-warning context and contraindication/dosing safety) are not addressed.
Category Scores
Accurate Statements
Indomethacin is a prescription nonsteroidal anti-inflammatory drug (NSAID).
CLINICAL PHARMACOLOGY (describes indomethacin as an NSAID).
Indomethacin is used to treat some types of arthritis.
INDICATIONS AND USAGE (rheumatoid arthritis, ankylosing spondylitis, osteoarthritis).
Indomethacin is used for certain arthritis-related symptoms.
CLINICAL PHARMACOLOGY (relief of symptoms; reduction of pain/fever/swelling/tenderness).
Indomethacin reduces inflammation, pain, and fever.
CLINICAL PHARMACOLOGY (relief of pain; reduction of fever; suppression/diminish inflammation; gout and RA effects).
Indomethacin reduces inflammation, pain, and fever by lowering production of prostaglandins.
CLINICAL PHARMACOLOGY (potent inhibitor of prostaglandin synthesis; mediators of inflammation and sensitization).
NSAIDs can be risky for people with a history of stomach ulcers or gastrointestinal bleeding.
Gastrointestinal Effects (prior history of ulcer disease and/or GI bleeding increases GI bleed risk; extreme caution).
NSAIDs can be risky for people with certain heart or blood vessel conditions.
WARNINGS (Cardiovascular Effects: patients with known CV disease or risk factors may be at greater risk).
NSAIDs can be risky for people with aspirin-sensitive asthma.
CONTRAINDICATIONS and WARNINGS/Anaphylactic/Anaphylactoid Reactions and PRECAUTIONS (Preexisting Asthma; aspirin triad; should not be administered to aspirin triad patients).
Unsupported Statements
Indomethacin is used to treat conditions where inflammation and pain are major parts of the problem.
Broader generalization than the specific label phrasing; label provides specific indications rather than this general condition-description.
Indomethacin is used to treat acute inflammatory flares.
Overly generic; the label specifies 'acute flares of chronic disease' in rheumatoid arthritis rather than 'acute inflammatory flares' broadly.
Indomethacin is commonly prescribed for gout attacks.
The label lists 'acute gouty arthritis' as an indication but does not state or support 'commonly prescribed' or prescribing frequency.
Indomethacin is used for other inflammatory joint conditions.
Label provides a finite list of approved active stages; does not support use for 'other inflammatory joint conditions' beyond those listed.
Indomethacin is used for pain and inflammation linked to musculoskeletal problems when an NSAID is appropriate.
Not supported by the provided label language; label does not include this general 'musculoskeletal problems' or decision-triage phrasing.
Contradictions
Important Omissions
Boxed-warning elements and key scope/limits (e.g., NSAID class boxed risks and the specific CABG perioperative contraindication) are not addressed by the provided claims.
Importance:
High
Dose/administration safety guidance (e.g., use lowest effective dose for shortest duration) is not included in the evaluated claims.
Importance:
High
Contraindications beyond general hypersensitivity/asthma concepts (e.g., perioperative pain in CABG setting) are not addressed by the evaluated claims.
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Several claims are general or unsupported (e.g., 'commonly prescribed', 'other inflammatory joint conditions', and musculoskeletal generalization). The evaluation also did not cover high-priority label safety elements (boxed warning/CABG contraindication/dosing safety), increasing the chance of incomplete label-aligned risk communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overbroad/generalized indication and prescribing-frequency claims not supported by the provided label text; high-priority boxed-warning/contraindication/dosing safety elements not addressed by the claims.
Suggested Improvement
Restrict indication statements to the specific labeled indications (rheumatoid arthritis including acute flares of chronic disease, ankylosing spondylitis, osteoarthritis, acute painful shoulder bursitis/tendinitis, and acute gouty arthritis) and avoid claims about common prescribing frequency. Add label-supported high-priority safety information (use lowest effective dose for shortest duration; boxed warnings and the CABG perioperative contraindication).